10-Q: Quarterly report
Bone Biologics Announces Pricing of $2.0 Million Public Offering
Bone Biologics Reports Progress With NB1 Clinical Program
Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors
Bone Biologics Regains Compliance With Nasdaq Continued Listing Requirements
Bone Biologics Announces 1-for-8 Reverse Stock Split
No Data